| PubMed |
Abstract |
RScore(About this table) |
| 18599602 |
Watabe M, Nakaki T: Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells. Mol Pharmacol. 2008 Oct;74(4):933-40. Epub 2008 Jul 3.
|
361(4,5,6,6) |
Details |
| 18579341 |
Sai Y, Wu Q, Le W, Ye F, Li Y, Dong Z: Rotenone-induced PC12 cell toxicity is caused by oxidative stress resulting from altered dopamine metabolism. Toxicol In Vitro. 2008 Sep;22(6):1461-8. Epub 2008 May 4.
Tyrosine hydroxylase (TH) and vesicular monoamine transporter 2 (VMAT (2)) were markedly down-regulated, and dopamine transporter (DAT) was up-regulated in the cells. |
2(0,0,0,2) |
Details |
| 15384065 |
Zhu C, Vourc'h P, Fernagut PO, Fleming SM, Lacan S, Dicarlo CD, Seaman RL, Chesselet MF: Variable effects of chronic subcutaneous administration of rotenone on striatal histology. J Comp Neurol. 2004 Oct 25;478(4):418-26.
Confocal microscopy analysis showed that the vesicular monoamine transporter (VMAT2) was decreased in parallel with TH-IR, strongly suggesting a loss of striatal DA nerve terminals in animals with diffuse or central TH-IR loss. |
1(0,0,0,1) |
Details |